Literature DB >> 29523953

Comparison of three classifications for lymph node evaluation in patients undergoing total mesorectal excision for rectal cancer.

Johannes Fritzmann1, Pietro Contin2, Christoph Reissfelder3, Markus W Büchler2, Jürgen Weitz3, Nuh N Rahbari3, Alexis B Ulrich2.   

Abstract

PURPOSE: The present study compared the prognostic value of the lymph node ratio (LNR) and the 6th and the 7th TNM edition as three different lymph node classifications for rectal cancer patients.
METHODS: A total of 630 patients who underwent total mesorectal excision for primary rectal cancer between October 2001 and December 2007 were included. Prognostic factors of overall survival were analyzed using Cox proportional hazards models.
RESULTS: The median follow-up was 36.1 months and the 5-year overall survival rate was 70.3 ± 4.7%. The median number of lymph nodes was 15.0 (12.0-19.0). All three lymph node evaluations correlated with survival (p < 0.0001). The assessment of nodal status in the 7th TNM edition enabled further prognostic stratification. The prognostic value of the three classifications were independent of neoadjuvant therapy and lymph node count. On multivariate analyses, the N2 stage of the 6th TNM edition (Hazard ratio 2.08; 95% confidence interval 1.21-3.58) and the N2b stage of the 7th TNM edition (2.18; 1.17-4.07) correlated with poor survival. A LNR of 0.42-0.69 was also associated with unfavorable prognosis (2.97; 1.46-6.03), as was an LNR > 0.69 (2.51; 1.04-6.05). The LNR did not provide prognostic information in addition to the N stage of the TNM classifications.
CONCLUSIONS: The evaluated lymph node classifications were of comparable prognostic utility in patients with rectal cancer. The LNR did not provide prognostic information in addition to the N stage of the TNM classifications.

Entities:  

Keywords:  Lymph node; Metastasis; Rectal cancer; Total mesorectal excision

Mesh:

Year:  2018        PMID: 29523953     DOI: 10.1007/s00423-018-1662-5

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  35 in total

1.  Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure?

Authors:  Nuh N Rahbari; Alexis B Ulrich; Thomas Bruckner; Marc Münter; Axel Nickles; Pietro Contin; Thorsten Löffler; Christoph Reissfelder; Moritz Koch; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

Review 2.  [Update S3-guideline "colorectal cancer" 2008].

Authors:  W Schmiegel; A Reinacher-Schick; D Arnold; U Graeven; V Heinemann; R Porschen; J Riemann; C Rödel; R Sauer; M Wieser; W Schmitt; H-J Schmoll; T Seufferlein; I Kopp; C Pox
Journal:  Z Gastroenterol       Date:  2008-08       Impact factor: 2.000

3.  The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients.

Authors:  Robert Rosenberg; Jutta Engel; Christiane Bruns; Wolfgang Heitland; Nikolaus Hermes; Karl-Walter Jauch; Reinhard Kopp; Eberhard Pütterich; Reinhard Ruppert; Tibor Schuster; Helmut Friess; Dieter Hölzel
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

4.  Local recurrence following 'curative' surgery for large bowel cancer: II. The rectum and rectosigmoid.

Authors:  R K Phillips; R Hittinger; L Blesovsky; J S Fry; L P Fielding
Journal:  Br J Surg       Date:  1984-01       Impact factor: 6.939

5.  No downstaging after short-term preoperative radiotherapy in rectal cancer patients.

Authors:  C A Marijnen; I D Nagtegaal; E Klein Kranenbarg; J Hermans; C J van de Velde; J W Leer; J H van Krieken
Journal:  J Clin Oncol       Date:  2001-04-01       Impact factor: 44.544

6.  Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period.

Authors:  Robert Rosenberg; Jan Friederichs; Tibor Schuster; Ralf Gertler; Matthias Maak; Karen Becker; Anne Grebner; Kurt Ulm; Heinz Höfler; Hjalmar Nekarda; Jörg-Rüdiger Siewert
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

7.  The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer.

Authors:  Frédérique Peschaud; Peschaud Frédérique; Stéphane Benoist; Benoist Stéphane; Catherine Julié; Julié Catherine; Alain Beauchet; Beauchet Alain; Christophe Penna; Penna Christophe; Philippe Rougier; Rougier Philippe; Bernard Nordlinger
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

8.  The influence of the number of retrieved lymph nodes on staging and survival in patients with stage II and III rectal cancer undergoing tumor-specific mesorectal excision.

Authors:  Young-Wan Kim; Nam-Kyu Kim; Byung-Soh Min; Kang-Young Lee; Seung-Kook Sohn; Chang-Hwan Cho
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

9.  Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy.

Authors:  Sherif R Z Abdel-Misih; Lai Wei; Al B Benson; Steven Cohen; Lily Lai; John Skibber; Neal Wilkinson; Martin Weiser; Deborah Schrag; Tanios Bekaii-Saab
Journal:  J Natl Compr Canc Netw       Date:  2016-12       Impact factor: 11.908

10.  Positive lymph node retrieval ratio optimises patient staging in colorectal cancer.

Authors:  S J Moug; J D Saldanha; J R McGregor; M Balsitis; R H Diament
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more
  2 in total

1.  A Preoperative Scoring System to Predict the Risk of Inadequate Lymph Node Count in Rectal Cancer.

Authors:  Hao Zhang; Chunlin Wang; Yunxiao Liu; Hanqing Hu; Guiyu Wang
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

2.  Lymph Node Ratio as a Prognostic Marker in Rectal Cancer Survival: A Systematic Review and Meta-Analysis.

Authors:  Uday Karjol; Pavan Jonnada; Ajay Chandranath; Sushma Cherukuru
Journal:  Cureus       Date:  2020-05-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.